MI-CP151 was a stage 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre analyze to evaluate several intravenous doses of sifalimumab, in adult people with dermatomyositis or polymyositis (NCT00533091). Main trial objectives were to evaluate the safety and tolerability of sifalimumab in dermatomyositis or polymyositis patients, although one of many explorator... https://emiliotydhj.atualblog.com/37063664/what-does-nemifitide-ditfa-mean